Bee venom peptide melittin prevents cardiac hypertrophy by targeting ACE and NF-κB pathways
Bee venom, with melittin as its dominant active peptide, prevented cardiac hypertrophy in mice by downregulating ACE, renin, and the JAK2/NF-κB inflammatory signaling cascade.
Quick Facts
What This Study Found
Melittin identified as dominant BV component. BV prevented ECG and echo abnormalities, reversed morphological and histological heart changes, downregulated hypertrophy markers (β-MHC, ANP, BNP), ACE, and IL-1β, and inhibited JAK2/NF-κB signaling in ISO-induced cardiac hypertrophy.
Key Numbers
How They Did This
UPLC-Q/TOF-MS for BV characterization, isoproterenol-induced cardiac hypertrophy in mice (in vivo) and cardiomyocytes (in vitro), ECG, echocardiography, histopathology, network pharmacology, Western blot, and RT-qPCR.
Why This Research Matters
Cardiac hypertrophy progresses to heart failure, a leading cause of death. Bee venom peptides, particularly melittin, offer a natural peptide-based therapeutic approach targeting both the renin-angiotensin system and inflammatory pathways simultaneously.
The Bigger Picture
Venom-derived peptides continue to yield therapeutic candidates. Melittin's dual action on ACE/renin (blood pressure) and NF-κB (inflammation) pathways mirrors the multi-target approach increasingly valued in cardiovascular medicine.
What This Study Doesn't Tell Us
Preclinical study in mice. Bee venom is a complex mixture—clinical translation requires purified melittin. Safety profile of repeated melittin administration needs evaluation. ISO-induced hypertrophy is a simplified model.
Questions This Raises
- ?Can purified melittin reproduce all of bee venom's cardioprotective effects?
- ?How does melittin compare to ACE inhibitors for cardiac hypertrophy?
- ?What is the therapeutic window for melittin given its known cytotoxicity?
Trust & Context
- Key Stat:
- Dual ACE + NF-κB inhibition Bee venom peptide melittin targets both the renin-angiotensin system and inflammatory pathways to prevent cardiac hypertrophy
- Evidence Grade:
- Preclinical in vivo and in vitro study with network pharmacology validation. Good mechanistic evidence but limited to animal models.
- Study Age:
- Published in 2025.
- Original Title:
- Bee venom alleviates isoproterenol-induced cardiac hypertrophy via JAK2/NF-κB signaling cascade.
- Published In:
- Tissue & cell, 97, 103077 (2025)
- Authors:
- Shi, Peiying, Han, Shuo, Sun, Yang(4), Li, Mengmeng, Xu, Xueling
- Database ID:
- RPEP-13572
Evidence Hierarchy
Frequently Asked Questions
Can bee venom treat heart problems?
This preclinical study shows bee venom, primarily through its main peptide melittin, prevented abnormal heart muscle thickening in mice by reducing inflammation and blocking angiotensin-converting enzyme (ACE). However, this is early research and bee venom has known toxicity concerns that need to be addressed.
What is melittin?
Melittin is the main bioactive peptide in bee venom, making up about 50% of its dry weight. It is a 26-amino acid peptide known for membrane-disrupting activity. This study reveals it also has cardiovascular protective properties through ACE and NF-κB pathway modulation.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-13572APA
Shi, Peiying; Han, Shuo; Sun, Yang; Li, Mengmeng; Xu, Xueling. (2025). Bee venom alleviates isoproterenol-induced cardiac hypertrophy via JAK2/NF-κB signaling cascade.. Tissue & cell, 97, 103077. https://doi.org/10.1016/j.tice.2025.103077
MLA
Shi, Peiying, et al. "Bee venom alleviates isoproterenol-induced cardiac hypertrophy via JAK2/NF-κB signaling cascade.." Tissue & cell, 2025. https://doi.org/10.1016/j.tice.2025.103077
RethinkPeptides
RethinkPeptides Research Database. "Bee venom alleviates isoproterenol-induced cardiac hypertrop..." RPEP-13572. Retrieved from https://rethinkpeptides.com/research/shi-2025-bee-venom-alleviates-isoproterenolinduced
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.